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Metastatic bone pain is a significant cause of morbidity in patients with advanced cancer
and greatly reduces quality of life. Standard palliative treatments such as opioids may
not provide effective relief of metastatic bone pain, particularly acute breakthrough pain,
without unacceptable side effects at the high doses required. A mouse model of metastatic
bone pain has been developed in which tumor cells are injected directly into the marrow
space of mice femora. As the tumor cells proliferate, mice display reproducible behaviors
associated with pain, such as flinching or guarding the affected limb, that increase as bone
destruction progresses. The model also enables measurement of other endpoints, includ-
ing tumor growth and migration, and monitoring of relevant cell types such as osteoclasts,
macrophages, and neurons. Mouse studies have provided important information on the
mechanisms behind metastatic bone pain and the specific effects of potential therapies.
These studies have demonstrated that metastatic bone disease is caused by multiple fac-
tors and that osteoclasts are particularly important in pain generation through destruction
of bone and nerve fibers and acidotic stimulation of pH-sensitive receptors. Clinical studies
with bisphosphonates demonstrate that these agents provide relief of metastatic bone
pain, and preliminary experiments using the mouse model suggest that this may occur
via multiple mechanisms. Further studies are under way.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Pain is a highly debilitating symptom for patients with cancer,
causing disability, immobility, and reduced quality of life.
Bone metastases are the most common cause of cancer pain,1
and up to two-thirds of patients with bone metastases will
suffer severe pain.2 Effective treatments for metastatic bone
pain (MBP) are therefore an essential part of cancer care.
MBP is a progressive condition. Most patients initially
experience intermittent dull aches, and over a period of
weeks or months, this becomes progressively more severe
and constant.1,3 In addition, most patients with bone metas-
tases experience acute episodes of severe breakthrough pain
that are often localized to a particular area.4,5 The most com-
mon cause of breakthrough pain is movement during normaler Ltd. All rights reserved
.activities such as turning in bed, standing, sitting, or cough-
ing; however, breakthrough pain can also be unrelated to
activity and less predictable. The degree of pain experienced
by patients cannot be predicted by tumor type, size, or loca-
tion or by number of bone metastases, and the pain produced
by a bone lesion is often disproportionate to the degree of
bone involvement.1 It is therefore likely that MBP has a com-
plex etiology. As cancer pain progresses in severity, it be-
comes increasingly detrimental to a patient’s quality of life.
Recommendations from the World Health Organization
state that patients should receive treatment for cancer pain
according to a three-step analgesic ladder with the aim of
achieving freedom from pain.6,7 The ladder comprises non-
opioid analgesics (e.g., aspirin and acetaminophen) for mild
cancer pain, weak opioids (e.g., codeine) for moderate pain,.
Fig. 2 – Radiograph of mouse pelvis and hind limbs after
injection of sarcoma cells into the femur. The amalgam plug
retaining the tumor cells within the femur is visible
(arrow).19
Fig. 3 – Radiographs of murine femora showing the pro-
gressive loss of mineralized bone caused by tumor growth.
Numbers indicate weeks post injection. Scale bar = 2 mm.37
E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 4 –8 5and strong opioids (e.g., morphine) for severe pain, in addition
to adjuvant treatments. However, freedom from severe break-
through pain caused by bone metastases is rarely achieved
because patients titrate their opioid doses to avoid the signif-
icant side effects of high doses, such as constipation or seda-
tion.8,9 Although radiotherapy may assist in providing pain
relief for patients with localized MBP, there is still a significant
need for improved pain-relief strategies.
2. Development of metastatic bone cancer
Bone is a common metastatic site.10,11 Metastatic cells from
the primary tumor, e.g., breast or prostate cancers, have a
high likelihood of being carried to bone because of the high
blood flow in bone tissue. Tumor cells express adhesive mol-
ecules on their surfaces that enable binding to marrow stro-
mal cells and bone matrix. In addition, bone is a rich source
of immobilized growth factors that promote tumor cell prolif-
eration once metastatic cells have become resident. As bone
metastases grow, they release various factors that stimulate
the activity of osteoclasts or osteoblasts, leading to bone
destruction or formation, respectively, and disruption of the
normal bone remodeling process. It is this disruption that is
the main cause of metastatic bone disease and its resulting
sequelae, such as fractures and hypercalcemia. Metastasis
to bone frequently occurs before a patient is aware that they
have cancer, and MBP is often the first symptom to alert a pa-
tient to the disease.
Traditionally, bone metastases have been classified as
either osteolytic (bone destroying) or osteoblastic (bone form-
ing). It is now clear that these activities are linked and that al-
most all metastatic tumors induce a combination of bone
destruction and formation, with the overall phenotype indic-
ative of the predominating activity induced by the individual
tumor (Fig. 1).10,11 Although prostate cancer causes mainly
osteoblastic lesions, analysis of bone markers has demon-
strated that this tumor has some of the highest levels of bone
destruction of any tumor type.12
3. Mouse model of metastatic bone pain
To investigate the mechanisms behind MBP, a mouse model
has been developed.13–15 Tumor cells are injected directly into
the femoral marrow space and retained using dental amal-Fig. 1 – Spectrum of bone lesion characteristics in various
types of cancer.gam, which prevents invasion of adjacent soft tissues
(Fig. 2). As the tumor develops, the resulting bone lesions be-
come radiologically apparent (Fig. 3). Injection of different
types of tumor cells results in altered patterns of bone le-
sions, mirroring the clinical picture in patients with different
primary cancers. Injected mice display pain-associated
behaviors such as flinching or guarding of the affected limb
that are reproducible and can be quantified during experi-
mental analysis (Fig. 4). Pain behaviors are spontaneous but
can be exacerbated by palpation, similar to movement-in-
duced breakthrough pain in humans, and the extent of
pain-associated behavior correlates with the degree of bone
destruction.
In addition to pain-associated behaviors and bone destruc-
tion, the murine model of MBP has other measurable end-
points. Tumor cells can be stably transfected with a
fluorescent marker enabling observation of tumor growth
and migration within the bone (Fig. 5), which indicates dis-
ease progression. In addition, well-characterized markers
are available for many relevant cell types. These have demon-
strated that bone lesions are characterized by osteoclast pro-
Fig. 6 – Mechanisms driving metastatic bone pain (adapted
from Ref. [13]). Abbreviations: ET, endothelin; IL, interleukin;
NGF, nerve growth factor; PG, prostaglandin; TNF, tumor
necrosis factor.
Fig. 4 – Changes in pain behavior over time following tumor
cell injection (2472 sarcoma cells) into the femur of C3H
mice compared with sham injection (*P < 0.05).
Fig. 5 – Progression of fluorescent-labeled sarcoma cells on
different numbers of days post injection into a mouse
femur. On day 6, tumor cells remain close to the injection
site (indicated by arrow). By day 14, cells have proliferated
and migrated throughout the entire marrow space (original
injection site indicated by *).
6 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 4 –8liferation or hypertrophy, macrophage infiltration, and neuro-
nal injury or reorganization.13–15 Combining measures of
behavior, bone destruction, and cellular activity allows amore
comprehensive understanding of the pathophysiology of MBP.
An important question is how closely the mouse model
mirrors the principal characteristics of MBP in humans. It is
clear that the model displays several key features of clinical
disease, such as pain behaviors and tumor progression.13 In
addition, similarities have been observed regarding the rela-
tive efficacy of treatments. In humans, much higher doses
of opioids are required to alleviate MBP than to relieve inflam-
matory pain. When this was assessed in the mouse model,the morphine dose required to block bone tumor-induced
pain behaviors was 10-fold higher than the dose required to
block inflammatory pain behaviors of similar magnitude in-
duced by hindpaw injection of Freund’s adjuvant.16 This illus-
trates that the model has the potential to provide information
on the possible clinical efficacy of novel palliative therapies
for MBP.
4. The role of osteoclasts in metastatic bone
pain
Mouse studies have provided important insights into the
mechanisms behind bone cancer pain in humans (Fig. 6). It
is clear that the osteoclast, as the cell primarily responsible
for bone destruction in metastatic disease, plays a central role
in pain generation via several mechanisms.13–15 Bone tissue,
including the periosteum (outer bone covering), mineralized
bone, and marrow, is extensively innervated by sensory neu-
rons. Osteoclast-induced bone destruction leads to bone
destabilization, which causes pain through stimulation of
mechanosensitive receptors in the periosteum. In addition,
osteoclasts create an acidic microenvironment during the
bone resorption process, stimulating pH-sensitive receptors.
Excessive osteoclast activity leads to destruction of sensory fi-
bers, causing neuropathic pain.17 Because osteoclast activa-
tion and proliferation are features of both osteolytic and
osteoblastic bone metastases, osteoclasts may play a role in
pain generation even when excessive bone loss does not oc-
cur. The osteoclast is therefore an attractive target for MBP
therapies. Importantly, mouse studies have demonstrated
that inhibiting osteoclast activity can reduce or prevent
pain-associated behaviors.18–20
MBP can be driven by other factors.3,13–15 Tumor growth
can cause pain through bone distention, which can result in
mechanical stress and sensory neuron compression. A large
proportion of the tumor mass may be composed of inflamma-
tory cells (e.g., macrophages). Both tumor cells and inflamma-
tory cells secrete a variety of cytokines and other factors,
including prostaglandins, endothelins, and nerve growth fac-
tor. Sensory neurons in bone express receptors that detect
E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 4 –8 7several of these products, leading to a pain response or pain
sensitization. In addition, proton release by inflammatory
cells can contribute to local acidosis. The multifactorial nat-
ure of bone cancer pain helps explain why the level of pain
does not necessarily correspond to the extent of bone involve-
ment and why different therapies are required for pain relief
at different stages of disease or for ongoing versus break-
through pain. Successful therapies need to target the compo-
nents individually or in combination.
5. Relief of metastatic bone pain with
bisphosphonates
Bisphosphonates are a standard treatment for preventing
skeletal complications in patients with metastatic bone dis-
ease. Because bisphosphonates inhibit osteoclast-induced
bone destruction, these agents could potentially be useful
for all patients with MBP. Several trials with bisphosphonates
have demonstrated a palliative effect.21–27 In particular, clini-
cal studies have shown that ibandronate, a single-nitrogen,
noncyclic bisphosphonate available in intravenous and oral
formulations, provides long-term MBP relief for up to 2 years
following standard dosing25–27 and rapid pain relief with
intensive dosing on consecutive days (loading dose).28,29 In
all cases, pain relief with ibandronate was associated with
significant improvements in patient quality of life.
The mechanisms of action of bisphosphonates in relieving
MBP have not been elucidated fully, although they are under
active investigation. Alendronate, a bisphosphonate not indi-
cated for metastatic bone disease but widely used for treat-
ment of osteoporosis, is currently the only agent in this
class to have been studied in detail in the mouse model.17
In mice injected with labeled sarcoma cells, alendronate
treatment markedly reduced ongoing and movement-evoked
pain behaviors, osteoclast activity, tumor-induced bone
destruction and resorption, sensory nerve fiber destruction,
and neurochemical changes, although overall tumor burden
was not affected. Although alendronate is not indicated for
metastatic bone disease, these experiments demonstrate that
bisphosphonates have multiple effects that may contribute to
relief of MBP. Studies using bisphosphonates with clinically
proven palliative benefits, such as ibandronate, may reveal
more extensive effects. Murine experiments with ibandro-
nate, including loading-dose treatment, are under way. These
will also investigate the potential of ibandronate to attenuate
disease progression through osteoclast inhibition or direct
anti-tumor30–35 or anti-angiogenic36 effects suggested by
in vitro studies.
6. Discussion
MBP remains one of the most significant causes of morbidity
among patients with advanced cancer. Bone metastases
cause ongoing pain that progresses in severity and becomes
constant over time, as well as severe breakthrough pain that
can be spontaneous or movement evoked. Current treatment
options may be ineffective or cause unacceptable side effects.
Experiments using a mouse model suggest that MBP is caused
by multiple mechanisms. Because of this, successful pallia-
tion of MBP may require therapies that act via different mech-anisms at different stages of disease. All tumor types
metastasizing to bone induce bone destruction through acti-
vation of osteoclasts, which can cause MBP through bone
destabilization, sensory neuron destruction, and the genera-
tion of acidosis. Initial studies suggest that bisphosphonates,
which inhibit osteoclast activation, may represent an impor-
tant therapeutic option for MBP. Murine studies with ibandro-
nate in MBP are under way, including studies of intensive
loading-dose treatment for pain relief. These may also deter-
minewhether ibandronate can attenuate disease progression,
which would have important clinical implications. Overall,
murine studies have revealed an important information on
the specific mechanisms that cause MBP. Further study is
needed to increase the current understanding and to trans-
late experimental findings into improved treatment options
for patients with advanced cancer.
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